Abstract Background Oncology patients are more at risk for drug related problems because of treatment with (combinations of) anticancer drugs, as they have a higher risk for organ failure or altered metabolism with progression of their disease. Objective The aim of this study was to characterize and to evaluate the frequency of potential drug related problems (pDRPs) among oncology patients. Setting Outpatient-and day-care centres for Internal and Pulmonary Medicine at the Deventer Hospital, Deventer, The Netherlands. Method A prospective, descriptive, observational study was carried out from March 2010 to March 2011 at the Deventer Hospital, Deventer, The Netherlands. All patients older than 18 years receiving anticancer drugs prescribed by an internal medicineoncologist or pulmonologist-oncologist were included. Main outcome measure The primary outcome was the number and type of pDRPs according to Dutch guidelines. Results Among 546 patients with cancer, 952 pDRPs were identified, of which 474 were oncology-related. These were mainly drug interactions (IA) (246 IA in 157 patients) and potential contraindications (pCI) (201 pCI in 143 patients). Conclusion Most identified pDRPs in cancer patients were IAs and pCIs and involved corticosteroids. The most frequently occurring oncology-related IAs were classified as minor or moderate levels of severity.
Introduction
The incidence of cancer has increased over time. In the Netherlands during 2010, 95,456 new cases of cancer were identified, an increase of 3.3 % compared with 2009 and of about 35 % compared with 2000. Of the newly identified cases in 2010, 42 % were between 60 and 75 years of age and 31 % over 75 years [1] .
For several reasons, oncology patients in particular need intensive medication monitoring and counselling. First, elderly patients often use more drugs as a result of comorbidities. This increases the risk of drug-related problems with anticancer drugs in these patients. The use of anticancer drugs often results in the use of other agents to reduce or prevent side-effects of the anticancer treatment, thereby increasing the interaction potential [2] . Furthermore, cancer itself increases the need for more medications. Cytotoxic agents have a narrow therapeutic window and a complex pharmacologic profile. In oncology patients, pharmacokinetic parameters can be altered by the disease itself or due to malnutrition, reduced levels of serum-binding proteins, oedema, or hepatic and/or renal dysfunction [3] . Patients with cancer are therefore more at risk for drug interactions. It has been shown that 20-30 % of adverse drug reactions can be attributed to drug interactions [2] . Oncology-related PDIs involve between 18 and 58 % of cancer patients [3] [4] [5] .
The management of cancer is multi-disciplinary. In The Netherlands, pharmaceutical care for cancer patients is mostly divided into two channels. Monitoring and dispensing of supportive care agents is performed by the community pharmacist, generally outside the range of the hospital, whereas most anticancer drugs, except for oral formulations, are prepared at the Department of Clinical Pharmacy and administered on an oncology ward of a hospital. This can lead to errors in medication information transfer and unnoticed drug-related problems (DRPs). Therefore an actual and accurate list of current medications is a major element in identifying potential DRPs.
Aim of the study
The aim of this study was to characterize and to evaluate the frequency of potential drug-related problems (pDRPs) among oncology patients.
Method

Setting and patients
This prospective, descriptive, observational study was carried out from March 2010 through March 2011 at the Deventer Hospital, Deventer, The Netherlands. The Deventer Hospital is a teaching hospital (405 clinical beds) located in the eastern region of The Netherlands. The hospital serves a catchment population of about 180,000 residents.
Included were patients older than 18 years receiving anticancer drugs, including cytotoxic agents, hormones and biologicals, which were prescribed by a medical oncologist or pulmonologist-oncologist. Participants were recruited to the study through an intake appointment with a nurse oncology consultant. Intake with the nurse oncology consultant took place when a patient was diagnosed with (relapsed) cancer and could be considered for anticancer drugs therapy, or prior to change of anticancer drug treatment regimen due to progression. In 2009, 558 oncology patients had a first appointment with the nurse oncology consultant prior to treatment with anticancer agents or before change of treatment regimen.
Patients were excluded from the study if they received no anticancer drug therapy after intake. Patients gave written informed consent at the interview or with a returned list. A declaration of no objection was issued by the Dutch Central Committee on Research Involving Human Subjects accredited Medical Ethical Review Board of the Isala Clinics Zwolle, The Netherlands.
Data collection
All included patients received standard pharmaceutical care according to Dutch regulatory requirements [6] . For all patients, on intake with the nurse oncology consultant, a list of current medications, based on the drug dispensing history records of the community pharmacy, was made up and analysed by a pharmacist. The list of current medications, including identified pDRPs, was provided to the treating medical oncologist or pulmonologist-oncologist. Follow-up to identified problems was not part of this study.
Before the intake-appointment with the nurse oncology consultant, all patients, with the exception of those treated for lung cancer, received a written invitation for voluntary participation in a medication reconciliation interview with a pharmacist. They were asked to send in a self-made list of current medications by filling out an enclosed blank medication list. Patients treated for lung cancer were excluded from the medication reconciliation interview at the request of the pulmonologist, because of their poor prognosis. Patient characteristics, data on disease and treatment and laboratory data were obtained from the medical records database of the hospital. Comorbidities were classified according to International Statistical Classification of Diseases and Related Health Problems 10th Revision [7] .
Classification of DRPs
The potential DRPs in this study were analysed according to the Shumock-algorithm [8] . Identified potential DRPs were classified as presented earlier by van den Bemt et al. [9] . The items categorized as ''therapeutic errors'' were considered to be potential DRPs. Oncology-related drugdrug interactions were assessed according to the consensus of the Dutch multidisciplinary national expert group on interactions in oncology [10] . Other drug assessments were made according to the Dutch National Drug Database (Gstandard) [11] . Both quantify the strength of scientific evidence (''no evidence'' through 4 ''controlled, published interaction studies'') and clinical significance (A ''Clinically irrelevant effect'' through F ''Death'') according to the same classification system of 6 severity levels [12] .
Statistical analysis
Data were collected with the use of MS Excel 2003 and analysed with the use of MS Access 2003. Each consultation was considered to be a unique unlinked participant. Descriptive statistics were used to describe patient characteristics, frequency, type and classification of pDRPs.
Results
Patient characteristics
From March 2010 to March 2011, a total of 577 intakeappointments with 541 patients were made with the nurse oncology consultant. The inclusion of patients is shown in Fig. 1 . There were 87 intakes with 81 patients who were diagnosed with lung cancer. At the request of the pulmonologist, patients treated for lung cancer were not invited to participate in a medication reconciliation interview and their medications were analysed based on DDHRs alone. For a total of 392 intakes, patients were reminded to return their medication list by mail, and 201 (51.3 %) of these responded. The overall number of intakes per patient was 1.07 (range 1.00-1.08) times. The number of intakes with the nurse oncology consultant and the number of patients are considered equal and will further on be referred to as patients. The patient characteristics are shown in Table 1 .
Drug-related problems A total of 4,618 medication prescriptions were analysed in which 952 DRPs were identified in 546 patients, including patients treated for lung cancer, of which 474 (49.8 %) DRPs were oncology-related. For each patient the best fitting list of currently used medications was used for analysis. The identified DRPs are shown in Table 2 . The oncology-related DRPs that we detected were about equally divided over the categories ''contraindication'' (CI) and ''interaction'' (IA). There were 201 oncology-related CIs identified in 143 patients in a group of 546 (26.2 %) patients: 25 CIs could be attributed to an anticancer drug and 176 to a supportive care agent. There were 246 oncology-related IAs identified at least once in 157 patients in a group of 546 (28.8 %) patients, of which 26 were IAs between drugs of the same anticancer drug treatment regime. Ninety-four IAs could be attributed to an anticancer drug and 152 to a supportive care agent. In 70.4 % of the cases, oncology-related double medication included drugs that were part of the chemotherapy regimen, such as dexamethasone and prednisone. Other classified double medications included paracetamol (acetaminophen) and omeprazole. The items for the DRP categories CI and IA are shown in Tables 3 and 4 .
Of the 201 oncology-related CIs, 25 (12.4 %) were a CI for an anticancer drug and 176 (87.6 %) were a CI for oncology-related supportive care. The three most identified oncology-related CIs were hypertension (46.3 %), diabetes mellitus (22.4 %) and peptic ulcer (6.7 %). All were CIs The interacting agents dexamethasone in the IA with irinotecan or protein kinase inhibitors, both classified as 3A, were part of the anticancer treatment and was considered to be an intended IA. The IA of the supportive care drug prednisolone with dexamethasone, classified as 3D, was an IA between agents that were part of the anticancer treatment as well. IAs between other drugs in cancer patients could mainly be attributed to the IA between a renin-angiotensin system (RAAS) inhibitor and a diuretic (17.5 %) and between a RAAS-inhibitor and an NSAID (8.5 %).
Discussion
In this study, most CIs with an anticancer drug involved fluoropyrimidines and most CIs with a supportive care agent involved corticosteroids. However, all CIs, i.e. comorbidities, were adequately managed, and, as a consequence, were not considered to be of clinical relevance. Most IAs related to the use of supportive care drugs were classified as moderate (70.4 %). The most frequently identified IA with a supportive care drug was a Mean no. of other drugs ± SD 4.7 ± 3.4
Follow-up (3 months) Died 52 (9.5 %) corticosteroid with a NSAID (65.1 %). However, in 68 of the 99 (68.7 %) cases, a proton pump inhibitor was already prescribed, a required action to reduce the risk of peptic ulcer, or the use of the NSAID was not chronic. Although there are methodological differences, the five most identified oncology-related IAs by this study are in agreement with those identified by Riechelmann et al. [3] as well as those identified by Van Leeuwen et al. [5] . Our study results are dissimilar to those of Voll et al. [4] , because of a high percentage of antiretroviral drugs prescriptions in their patients, causing specific IAs. Both
MOs medication orders
Riechelmann et al. and Van Leeuwen et al. used The Drug
Interactions Facts [13] as a drug-interaction-database whereas in this study the Dutch national drug database [11] , including the consensus-based management of anticancer drug interactions, was used [10] . Van Leeuwen et al. found a higher percentage of patients with IAs with anticancer drugs: 138 IAs occurring at least once in 161 patients in a group of 278 (58 %) patients. This is mainly due to the inclusion of IAs (classified by the authors as major) with potential QT-interval prolongation and/or torsades de pointes-inducing properties according to the Arizona-list [14] . These QT IAs in the study by Van Leeuwen are responsible for almost one-third of the IAs found.
On behalf of the pulmonologist, patients treated for lung cancer were not invited for voluntary participation. The number of patients treated for lung cancer in this study, about 15 %, is substantial. In general, patients treated for lung cancer are more ill and have a worse prognosis as compared with breast and/or colon cancer (the two most commonly occurring types of cancer). In our opinion, patients treated for lung cancer should therefore not be excluded from the descriptive analysis of occurring pDRPs despite the fact that their medications were analysed only based on DDHRs. COXIB cyclo-oxygenase-2 inhibitor, PKI protein kinase inhibitor a Classification of levels of severity and evidence by documentation of oncology related drug interactions [13] b Combination of irinothecan and dexamethasone within the same treatment protocol is regarded as an intended drug interaction. 
